The Top Biopharma Stories of 2019

- A $74 billion big pharma acquisition.

- An unexpected resignation that ended a definitive era for the Food and Drug Administration.

- The failure and highly controversial revival of what was hitherto regarded as a promising drug for Alzheimer's disease.

- A major regulatory scandal concerning one of the first-ever approved gene therapies.

- The first FDA approval of a drug to tackle a devastating blood disorder and the ongoing scrutiny over drug prices.

 

These were just some of the biggest events in the biopharma industry in 2019.

 

Take a closer look at these stories that will continue to reverberate as the industry enters the third decade of the 21st century.